Cargando…
Tumor-derived OBP2A promotes prostate cancer castration resistance
Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer (PCa); although most patients initially respond to ADT, almost all cancers eventually develop castration-resistant PCa (CRPC). Currently, most research focuses on castration-resistant tumors, and the role of tumors...
Autores principales: | Jeong, Ji-Hak, Zhong, Shangwei, Li, Fuzhuo, Huang, Changhao, Chen, Xueyan, Liu, Qingqing, Peng, Shoujiao, Park, HaJeung, Lee, You Mie, Dhillon, Jasreman, Luo, Jun-Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789742/ https://www.ncbi.nlm.nih.gov/pubmed/36547668 http://dx.doi.org/10.1084/jem.20211546 |
Ejemplares similares
-
Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer
por: Zhong, Shangwei, et al.
Publicado: (2021) -
Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
por: Zhong, Shangwei, et al.
Publicado: (2021) -
Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
por: Zhong, Shangwei, et al.
Publicado: (2022) -
Beam Profile from OBP
por: van Apeldoorn, J, et al.
Publicado: (1975) -
Identification of Odorant-Binding Proteins (OBPs) and Functional Analysis of Phase-Related OBPs in the Migratory Locust
por: Guo, Wei, et al.
Publicado: (2018)